Key Highlights

  • IXICO Plc (LSE:IXI) closed its financial year on 30 September 2026 after guiding to revenue of at least £8.0m, roughly 22% higher than FY25.
  • First-half revenue rose 23% to £3.9m, while the order book climbed to £18.1m from £13.1m a year earlier.
  • The company reaffirmed its outlook in July despite cancellations of certain Huntington's disease trials by clients.
  • Investors are now watching for the year-end trading update, order book conversion and progress on partnerships around its AI-driven IXI platform.

Why IXICO Is in Focus Today

IXICO Plc (LSE:IXI), the AIM-listed neuroscience imaging and biomarker analytics company, is drawing renewed attention from small-cap healthcare investors on 12 October 2026. The company has now passed the end of its financial year on 30 September 2026, which places the spotlight firmly on whether the business delivered the revenue upgrade it flagged during the summer.

In early July, IXICO told the market it expected FY26 revenue of at least £8.0m, ahead of existing market expectations and about 22% above the previous year. That guidance came after a period of contract wins, extensions and a broader client base, and it has shaped how investors are approaching the stock as the year-end reporting cycle begins.

With the books now closed, attention across UK healthcare investing communities has turned to the final numbers and the forward order book.

A Business Built on AI-Driven Brain Imaging

IXICO supports pharmaceutical and biotech companies running clinical trials in neurological disorders such as Alzheimer's disease, Parkinson's disease and Huntington's disease. Its IXI platform collects imaging data from trial sites around the world, and its scientists turn complex scans into measurements that help sponsors judge whether an experimental therapy is working.

The company has supported hundreds of neurological trials and analysed hundreds of thousands of scans through an established network of imaging centres. During the first half of FY26, it deployed the tenth version of its platform, which management said significantly improved data upload and analysis speeds.

IXICO has also positioned itself as a "TechBio" business, combining software, artificial intelligence and scientific services. The company has said its AI brain imaging tool matches or beats human experts on certain tasks.

Half-Year Numbers Set the Tone

The interim results for the six months to 31 March 2026 gave investors their clearest view of the business this year. Revenue increased 23% to £3.9m from £3.2m, driven by new contract wins, contract extensions and a higher volume of analyses. The order book rose to £18.1m at 31 March 2026, compared with £13.1m a year earlier, representing a multi-year high for the company.

Profitability remains a work in progress. The pretax loss widened to £1.6m from £0.9m as IXICO invested in its commercial team and platform. Sales and marketing costs rose 23% to £1.1m, and total operating expenses increased 19% to £3.3m. On an EBITDA basis, however, the loss narrowed to £0.5m from £0.7m, suggesting that operating leverage is starting to show through.

Chief Executive Bram Goorden described the company as being in a more stable and resilient position, and the market responded sharply on the day of the results, with the share price jumping about 30% in afternoon trading.

Navigating the Huntington's Setback

The path through FY26 has not been entirely smooth. In July, IXICO reported that certain Huntington's disease trials had been cancelled by sponsors. Importantly for shareholders, the company stated that its revenue outlook remained unchanged, pointing to diversification across therapeutic areas and clients.

Shortly afterwards, Chair Mark Warne increased his shareholding through a fresh share purchase. Director buying after a negative headline is often read as a sign of board confidence.

IXICO has also added commercial firepower. A new Chief Commercial Officer joined from a global contract research organisation, and the company has said it plans to accelerate business development activity. A collaboration with clinical trial technology provider Medidata was highlighted by management as a template for future partnerships that could widen IXICO's reach.

Sector Backdrop for Neuroscience Trials

Demand for advanced imaging in neurology trials has been supported by the arrival of disease-modifying Alzheimer's treatments and a growing focus on biomarkers, including blood-based tests. Regulators and drug developers increasingly rely on objective imaging endpoints, which plays directly into IXICO's area of expertise.

At the same time, biotech funding conditions remain uneven, and smaller sponsors can delay or cancel programmes when capital tightens. That makes contract diversification and order book visibility key metrics for investors following LSE:IXI.

What Investors Are Watching Next

Several near-term checkpoints are now in view. The first is the year-end trading update, which should confirm whether FY26 revenue met or exceeded the £8.0m guidance. The second is the size and quality of the order book entering FY27, which will indicate how much revenue is already contracted for the year ahead.

Investors will also look for progress towards EBITDA breakeven, any new partnership announcements similar to the Medidata arrangement, and updates on how the latest IXI platform version is helping the company win larger, longer studies.

Outlook

IXICO Plc (LSE:IXI) enters the new financial year with revenue momentum, a larger order book and a clearer commercial strategy than it had twelve months ago. The upcoming results will test whether that momentum can translate into improving margins. For now, the stock sits on watchlists as one of the more closely followed small-cap names in UK healthcare technology.